Marvel BiosciencesMBCOF +4.74%33 Quick Ratio is 0.18 as of Apr. 2026, which is 58% below its 10-year median of 0.43. GuruFocus rates MBCOF with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Marvel Biosciences ranks worse than 97.25% on this metric.
Marvel Biosciences has a quick ratio of 0.18. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Marvel Biosciences's Quick Ratio or its related term are showing as below:
MBCOF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.08 Med: 0.43 Max: 22.04
Current: 0.18
During the past 6 years, Marvel Biosciences's highest Quick Ratio was 22.04. The lowest was 0.08. And the median was 0.43.
MBCOF's Quick Ratio is ranked worse than 97.25% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs MBCOF: 0.18
Marvel Biosciences (OTCPK:MBCOF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Marvel Biosciences Quick Ratio Related Terms
Marvel Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Marvel Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Marvel Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marvel Biosciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Marvel Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Marvel Biosciences's Quick Ratio for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marvel Biosciences (MBCOF) has a Quick Ratio of 0.18 as of Apr. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Marvel Biosciences and its competitors. This is 58% below median its historical median of 0.43. Over the past decade, Marvel Biosciences' Quick Ratio has ranged from 0.08 to 22.04. According to the industry distribution chart, Marvel Biosciences ranks #1378 out of 1417 companies in the Biotechnology industry, placing it in the top 97.2%.
Is Marvel Biosciences' Quick Ratio too high?
Marvel Biosciences' current Quick Ratio of 0.18 is 58% below median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 22.04. The Biotechnology industry median Quick Ratio is 3.60. Marvel Biosciences' value of 0.18 is 95% below this industry median. Based on the distribution chart, Marvel Biosciences ranks #1378 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #1378 out of 1417 companies for Quick Ratio. This places Marvel Biosciences in the lower half of its industry. The industry median Quick Ratio is 3.60. Marvel Biosciences' value of 0.18 is 95% below this benchmark. Historically, Marvel Biosciences' own Quick Ratio has ranged from 0.08 to 22.04 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 3.60, Marvel Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marvel Biosciences's current Quick Ratio of 0.18 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Marvel Biosciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current Quick Ratio is 0.18, which is 58% below median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Quick Ratio of 0.18. The current Quick Ratio is 0.18, which is 58% below median its 10-year median of 0.43 and 95% below the Biotechnology industry median of 3.60. Marvel Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Quick Ratio is 0.18 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
33GF Score
Get the complete analysis for MBCOF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBCOF has been successfully added to your 
